Physician profile
James A Stallone
NPI 1144319096
$1,891.70
in general payments reported to CMS, 2019-2025
33 companies · $335 in 2025
The $335 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $367 · 2020: $146 · 2021: $40.64 · 2022: $223 · 2023: $256 · 2024: $525 · 2025: $335.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,115.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $249.98 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $209.46 | 2020-2025 | |
| Lilly USA, LLC | $185.70 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $164.16 | 2019-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $129.91 | 2019-2024 | Farxiga, Airsupra |
| Exact Sciences Corporation | $94.30 | 2023-2025 | Cologuard Collection Kit |
| Sumitomo Pharma America, INC. | $73.33 | 2024-2025 | Gemtesa |
| Radius Health, INC. | $72.53 | 2023-2025 | Tymlos |
| Philips North America LLC | $55.59 | 2024 | (Ck4) Mcot |
| Merck Sharp & Dohme LLC | $54.47 | 2019-2020 | |
| Esperion Therapeutics, INC. | $48.09 | 2024 | Nexletol |
| Regeneron Healthcare Solutions, INC. | $46.09 | 2019-2024 | Dupixent |
| Glaxosmithkline, LLC. | $45.44 | 2019-2024 | Trelegy Ellipta, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $38.82 | 2023-2024 | Eliquis |
| Bausch Health US, LLC | $37.91 | 2022-2023 | Wellbutrin, Aplenzin |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.54 | 2022 | |
| Inspire Medical Systems, INC. | $28.67 | 2025 | Inspire |
| Abbvie INC. | $27.81 | 2024 | |
| Janssen Pharmaceuticals, INC | $27.09 | 2019 | |
| Shield Therapeutics INC | $23.80 | 2023 | Accrufer |
| Daiichi Sankyo INC. | $23.73 | 2019 | |
| Genentech USA, INC. | $23.58 | 2019 | |
| Ibsa Pharma INC. | $22.81 | 2025 | Flector, Licart, Tirosint |
| Linus Health, INC. | $21.08 | 2024 | Core Cognitive Evaluation |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.08 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.77 | 2024 | |
| Horizon Therapeutics Plc | $19.49 | 2022 | |
| Seqirus USA INC | $18.15 | 2023 | Flucelvax Quadrivalent, Fluad Quadrivalent |
| Abbott Laboratories | $18.05 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.84 | 2025 | Euflexxa |
| Astellas Pharma US INC | $15.11 | 2024 | Veozah |
| Currax Pharmaceuticals LLC | $13.91 | 2024 | Contrave |
| Dexcom, INC. | $13.41 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Stallone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.